vs
EXACT SCIENCES CORP（EXAS）与StoneX Group Inc.（SNEX）财务数据对比。点击上方公司名可切换其他公司
StoneX Group Inc.的季度营收约是EXACT SCIENCES CORP的1.4倍（$1.2B vs $878.4M），StoneX Group Inc.净利率更高（11.6% vs -9.8%，领先21.4%），StoneX Group Inc.同比增速更快（81.0% vs 23.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-1.3B），过去两年StoneX Group Inc.的营收复合增速更高（53.5% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
StoneX集团是美国知名金融服务企业，核心业务覆盖商业套期保值、全球支付、证券、实物大宗商品、外汇，以及清算与执行服务六大板块，可为全球各类客户提供专业合规的多元化金融服务。
EXAS vs SNEX — 直观对比
营收规模更大
SNEX
是对方的1.4倍
$878.4M
营收增速更快
SNEX
高出57.9%
23.1%
净利率更高
SNEX
高出21.4%
-9.8%
自由现金流更多
EXAS
多$1.4B
$-1.3B
两年增速更快
SNEX
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.2B |
| 净利润 | $-86.0M | $139.0M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 15.4% |
| 净利率 | -9.8% | 11.6% |
| 营收同比 | 23.1% | 81.0% |
| 净利润同比 | 90.1% | 63.3% |
| 每股收益（稀释后） | $-0.45 | $2.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSNEX
| Q4 25 | $878.4M | $1.2B | ||
| Q3 25 | $850.7M | $32.7B | ||
| Q2 25 | $811.1M | $851.2M | ||
| Q1 25 | $706.8M | $820.4M | ||
| Q4 24 | $713.4M | $663.1M | ||
| Q3 24 | $708.7M | $31.1B | ||
| Q2 24 | $699.3M | $571.8M | ||
| Q1 24 | $637.5M | $509.2M |
净利润EXASSNEX
| Q4 25 | $-86.0M | $139.0M | ||
| Q3 25 | $-19.6M | $85.7M | ||
| Q2 25 | $-1.2M | $63.4M | ||
| Q1 25 | $-101.2M | $71.7M | ||
| Q4 24 | $-864.6M | $85.1M | ||
| Q3 24 | $-38.2M | $76.7M | ||
| Q2 24 | $-15.8M | $61.9M | ||
| Q1 24 | $-110.2M | $53.1M |
毛利率EXASSNEX
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | 3.7% | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | 3.0% | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASSNEX
| Q4 25 | -9.4% | 15.4% | ||
| Q3 25 | -3.0% | 0.3% | ||
| Q2 25 | -0.3% | -1.3% | ||
| Q1 25 | -13.6% | -1.0% | ||
| Q4 24 | -122.8% | -3.2% | ||
| Q3 24 | -5.6% | -0.0% | ||
| Q2 24 | -3.8% | -4.7% | ||
| Q1 24 | -16.7% | -2.5% |
净利率EXASSNEX
| Q4 25 | -9.8% | 11.6% | ||
| Q3 25 | -2.3% | 0.3% | ||
| Q2 25 | -0.1% | 7.4% | ||
| Q1 25 | -14.3% | 8.7% | ||
| Q4 24 | -121.2% | 12.8% | ||
| Q3 24 | -5.4% | 0.2% | ||
| Q2 24 | -2.3% | 10.8% | ||
| Q1 24 | -17.3% | 10.4% |
每股收益（稀释后）EXASSNEX
| Q4 25 | $-0.45 | $2.50 | ||
| Q3 25 | $-0.10 | $0.72 | ||
| Q2 25 | $-0.01 | $1.22 | ||
| Q1 25 | $-0.54 | $1.41 | ||
| Q4 24 | $-4.69 | $1.69 | ||
| Q3 24 | $-0.21 | $2.32 | ||
| Q2 24 | $-0.09 | $1.25 | ||
| Q1 24 | $-0.60 | $1.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.6B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.5B |
| 总资产 | $5.9B | $47.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASSNEX
| Q4 25 | $964.7M | $1.6B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | $858.4M | $1.3B | ||
| Q1 25 | $786.2M | $1.3B | ||
| Q4 24 | $1.0B | $1.4B | ||
| Q3 24 | $1.0B | $1.3B | ||
| Q2 24 | $946.8M | $1.2B | ||
| Q1 24 | $652.1M | $1.3B |
股东权益EXASSNEX
| Q4 25 | $2.4B | $2.5B | ||
| Q3 25 | $2.5B | $2.4B | ||
| Q2 25 | $2.5B | $2.0B | ||
| Q1 25 | $2.4B | $1.9B | ||
| Q4 24 | $2.4B | $1.8B | ||
| Q3 24 | $3.2B | $1.7B | ||
| Q2 24 | $3.2B | $1.6B | ||
| Q1 24 | $3.1B | $1.5B |
总资产EXASSNEX
| Q4 25 | $5.9B | $47.8B | ||
| Q3 25 | $5.9B | $45.3B | ||
| Q2 25 | $5.8B | $34.3B | ||
| Q1 25 | $5.7B | $31.3B | ||
| Q4 24 | $5.9B | $29.6B | ||
| Q3 24 | $6.7B | $27.5B | ||
| Q2 24 | $6.7B | $25.9B | ||
| Q1 24 | $6.4B | $25.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $-1.3B |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-1.3B |
| 自由现金流率自由现金流/营收 | 13.7% | -106.4% |
| 资本支出强度资本支出/营收 | 3.6% | 1.3% |
| 现金转化率经营现金流/净利润 | — | -9.08× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $3.5B |
8季度趋势，按日历期对齐
经营现金流EXASSNEX
| Q4 25 | $151.7M | $-1.3B | ||
| Q3 25 | $219.9M | $3.5B | ||
| Q2 25 | $89.0M | $1.5B | ||
| Q1 25 | $30.8M | $-154.5M | ||
| Q4 24 | $47.1M | $-477.8M | ||
| Q3 24 | $138.7M | $192.6M | ||
| Q2 24 | $107.1M | $-622.1M | ||
| Q1 24 | $-82.3M | $784.0M |
自由现金流EXASSNEX
| Q4 25 | $120.4M | $-1.3B | ||
| Q3 25 | $190.0M | $3.5B | ||
| Q2 25 | $46.7M | $1.5B | ||
| Q1 25 | $-365.0K | $-169.8M | ||
| Q4 24 | $10.7M | $-491.4M | ||
| Q3 24 | $112.6M | $175.9M | ||
| Q2 24 | $71.2M | $-640.5M | ||
| Q1 24 | $-120.0M | $766.6M |
自由现金流率EXASSNEX
| Q4 25 | 13.7% | -106.4% | ||
| Q3 25 | 22.3% | 10.7% | ||
| Q2 25 | 5.8% | 173.3% | ||
| Q1 25 | -0.1% | -20.7% | ||
| Q4 24 | 1.5% | -74.1% | ||
| Q3 24 | 15.9% | 0.6% | ||
| Q2 24 | 10.2% | -112.0% | ||
| Q1 24 | -18.8% | 150.5% |
资本支出强度EXASSNEX
| Q4 25 | 3.6% | 1.3% | ||
| Q3 25 | 3.5% | 0.1% | ||
| Q2 25 | 5.2% | 1.9% | ||
| Q1 25 | 4.4% | 1.9% | ||
| Q4 24 | 5.1% | 2.1% | ||
| Q3 24 | 3.7% | 0.1% | ||
| Q2 24 | 5.1% | 3.2% | ||
| Q1 24 | 5.9% | 3.4% |
现金转化率EXASSNEX
| Q4 25 | — | -9.08× | ||
| Q3 25 | — | 41.18× | ||
| Q2 25 | — | 23.52× | ||
| Q1 25 | — | -2.15× | ||
| Q4 24 | — | -5.61× | ||
| Q3 24 | — | 2.51× | ||
| Q2 24 | — | -10.05× | ||
| Q1 24 | — | 14.76× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SNEX
暂无分部数据
